MARLBOROUGH, Mass., April 7, 2026, 07:07 EDT
Hologic has locked in all the necessary regulatory sign-offs for its sale to Blackstone and TPG, with the $18.3 billion take-private transaction on track to wrap up around April 7. Chairman, President and CEO Steve MacMillan—who has led the company for years—will step down following the close, he confirmed.
Timing is key here. Nasdaq announced HOLX will be halted after Monday’s after-hours session, and—assuming the merger wraps up—stays halted on April 7, before suspension kicks in on April 8. S&P Dow Jones Indices has already slotted Hologic’s removal from the S&P 500 ahead of the April 9 open, with Casey’s General Stores lined up as its replacement.
Hologic last changed hands at $76.01, matching up with the $76 cash piece of the deal, and landing shy of the potential $79-a-share headline. The additional $3? That’s tied to a CVR—investors collect only if Hologic’s breast health sales reach set marks in fiscal 2026 and 2027.
Blackstone and TPG struck the buyout deal back in October, bringing in minority backers ADIA from Abu Dhabi and Singapore’s GIC. Hologic shareholders gave their sign-off in February. When the deal was first announced, Hologic said it planned to stick with its Marlborough base and would keep the Hologic brand once the transaction goes through.
The transaction takes a women’s health tech firm—best known for mammography equipment, cervical cancer screening, and other diagnostic devices—off the public exchanges. Hologic’s most recent annual filing singles out Siemens Healthineers and GE HealthCare as leading competitors when it comes to breast and skeletal health. In cytology, which covers lab work on cervical cell samples, Becton Dickinson gets the nod as the primary rival.
Hologic’s growth kept moving, though numbers were lumpy heading into the close. Last quarter, revenue ticked up 2.5% to $1.05 billion. Breast health added 1.8%, and surgical sales posted an 8.7% jump. Margins didn’t get much help: the company pointed to $15.3 million in tariff costs.
Lead independent director Amy Wendell thanked Steve, saying stakeholders owed him “a debt of gratitude.” MacMillan, 62, who took over as chief executive at Hologic back in 2013, described the job as “the greatest honor and privilege” of his career. The company plans to announce his successor when the deal closes. Hologic Investor Relations
Blackstone’s Ram Jagannath called Hologic “an outstanding global leader” in women’s health when the buyout went public. For TPG, John Schilling labeled the deal “a compelling opportunity” to support healthcare innovation. Both buyers are wagering that private hands can accelerate growth—even as established medtech players like Siemens Healthineers and GE HealthCare crowd the field. Hologic Investor Relations
One last hurdle stands in the way. Hologic noted that the deal’s close depends on meeting or waiving the usual conditions, and investors aren’t guaranteed the entire headline payout—the CVR is tied to how breast health sales play out. The company has also flagged possible hits from litigation, expenses tied to the transaction, and the risk that disruption could spill over to staff, customers or other partners.
